ArticleFrontiers in microbiology2025
Genome mining and OSMAC strategies unveil diverse secondary metabolites from the endophytic fungus
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Pigmented fungi derived from hot and cold deserts ecosystems: taxonomy, genomic and biotechnological approach.World journal of microbiology & biotechnology · 2026Review
- Global Research Landscape and Thematic Evolution of Fungi-Derived Antimicrobials Against Methicillin-ResistantBiology · 2026Review
- Rapid Discovery of Antifungal α-Pyrone Analogs fromJournal of fungi (Basel, Switzerland) · 2026Article
- Comparative genome mining and metabolomics reveal divergent NRPS-derived fengycin biosynthetic gene clusters inFEMS microbes · 2026Article
- All you need is fungi: Exploring secondary metabolites as a source of novel amoebicidal agents.Genetics and molecular biology · 2026Article
- Unveiling cryptic diversity ofIMA fungus · 2026Article
- Comparative Transcriptome Analysis ofMycobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal-derived bioactive natural products are a crucial resource for drug discovery; however, under standard laboratory cultivation conditions, fungi predominantly yield known and repetitively isolated metabolites. This metabolic constraint presents a major obstacle to the discovery of structurally novel and bioactive secondary metabolites. Recent advances in whole-genome sequencing have revealed that a significant portion of fungal biosynthetic gene clusters (BGCs) remain silent or unexpressed under conventional culture conditions, underscoring the importance of activating these cryptic BGCs. In this study, we systematically explored the biosynthetic potential of the terrestrial-derived fungus
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.